Leflunomid Tillomed

Leflunomide, the active ingredient in Leflunomid Tillomed, is an immunomodulatory agent presented as an oral tablet for systemic use. It is employed to modify disease activity in inflammatory joint disorders such as rheumatoid arthritis and psoriatic arthritis in adult patients.

GNH USA supplies Leflunomid Tillomed as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable logistics for global distribution. Clients benefit from comprehensive regulatory support and on‑time delivery across multiple continents.

Leflunomide is a disease‑modifying antirheumatic drug that targets inflammatory pathways in autoimmune arthritis. - Rheumatoid arthritis: reduces joint inflammation and slows structural damage in adult patients. - Psoriatic arthritis: improves skin and joint symptoms and limits disease progression. - Inadequate response to conventional DMARDs: provides an alternative oral option when other agents have failed.

Leflunomide may cause a range of adverse reactions, which are classified by frequency and severity.

Common Side Effects: - Diarrhoea: mild to moderate gastrointestinal upset. - Nausea: occasional feeling of queasiness. - Elevated liver enzymes: transient increase in ALT/AST. - Hypertension: rise in blood pressure. - Rash: non‑specific skin eruptions.

Serious or Rare Side Effects: - Severe liver injury: hepatitis or hepatic failure. - Bone marrow suppression: neutropenia, anaemia, thrombocytopenia. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Interstitial lung disease: progressive pulmonary fibrosis.

Before initiating Leflunomide, clinicians should evaluate several safety considerations to minimise risk. - Liver function: obtain baseline hepatic enzymes and monitor regularly. - Pregnancy: contraindicated; avoid use in women of childbearing potential. - Immunosuppression: assess risk of infections and vaccinate appropriately. - Hematology: perform baseline complete blood count and monitor for cytopenias. - Drug interactions: review concomitant medications that affect hepatic metabolism. - Store at ambient temperature: keep below 25 °C in original packaging, protect from moisture and light.

Leflunomide interacts with several agents that can alter its efficacy or increase toxicity.

Major Interactions (Avoid): - Teriflunomide with cholestyramine or activated charcoal: markedly reduces drug exposure. - Strong CYP1A2 inhibitors (e.g., fluvoxamine): increase teriflunomide plasma levels. - Hepatotoxic drugs (e.g., methotrexate, azathioprine): compound risk of liver injury.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect, monitor INR. - Live vaccines: increased risk of infection, avoid during therapy. - NSAIDs: additive risk of hypertension and renal impairment.